For most of its known history, N,N-dimethyltryptamine — DMT — has occupied a peculiar place in pharmacology. It is produced naturally in the human body, found in dozens of plant species, and has been consumed ceremonially in South America for centuries as a key component of the brew known as ayahuasca. Western clinical research began in the 1990s with Rick Strassman's pioneering human studies, and Brazilian groups have studied ayahuasca's effects for over two decades. But DMT remained at the margins of mainstream medicine — until 2025.

Two recent studies, published within six months of each other, have moved DMT from the margins of psychedelic research into the centre of clinical neuroscience. The first, published in Science Advances in August 2025, showed that DMT significantly reduces brain damage after stroke in animal models. The second, published in Nature Medicine in February 2026, reported the first placebo-controlled trial of intravenous DMT for major depressive disorder, with results comparable to psilocybin. Together, they suggest that a molecule best known for inducing intense visionary experiences may also protect and repair the brain through mechanisms that have nothing to do with hallucination.

Meanwhile, a separate and growing body of research — much of it from Brazilian universities since the early 2000s, with more recent contributions from groups in Spain, the Czech Republic, and the Netherlands — has been examining ayahuasca itself: not isolated DMT, but the full traditional brew, with all its pharmacological complexity. Brain imaging studies, trauma research, and large observational surveys are building a picture of a compound whose therapeutic potential may extend well beyond what any single alkaloid can deliver.

The second breakthrough arrived from a different direction entirely. David Erritzoe and colleagues at Imperial College London conducted a randomised, placebo-controlled trial of intravenous DMT in 34 adults with moderate-to-severe major depressive disorder [4]. The results, published in Nature Medicine in February 2026, showed that a single 10-minute DMT infusion, combined with structured therapeutic support, produced significantly greater improvement than placebo at two weeks — with a large effect size (d = 0.82) comparable to psilocybin trials. Benefits persisted for at least three months. No serious adverse events occurred.

Three aspects of the trial stand out. First, the speed: measurable improvement within a week, compared to four to six weeks for conventional antidepressants. Second, the duration: a single session producing months of benefit, unlike daily medication. Third, the practicality: intravenous DMT has a plasma half-life of minutes — not hours — with subjective effects lasting 10–30 minutes after a single dose. Even with preparation and monitoring, the entire clinical session takes around two hours — a fraction of the six to eight hours required for psilocybin therapy. (By contrast, in ayahuasca the experience lasts far longer. The harmala alkaloids inhibit the enzyme that normally breaks DMT down, extending its activity well beyond the peak. DMT plasma levels peak at around 1.5–2 hours after ingestion, but the subjective visionary peak varies considerably depending on the brew's composition and individual factors — from minutes to over an hour — while the full experience, shaped by both the sustained DMT and the harmala alkaloids' own milder psychoactive contributions, commonly fades out over 4–6 hours. Many participants also report an "afterglow" — a period of heightened clarity, emotional openness, and wellbeing — that can persist for days or even weeks [10]. This article's clinical sections refer to isolated, intravenous DMT unless stated otherwise.)

Perhaps most intriguingly, the intensity of participants' mystical-type experiences appeared to moderate the antidepressant response. Participants who reported the deepest experiences — characterised by feelings of unity, sacredness, and transcendence of time — showed the greatest reductions in depression scores. This finding complicates the hope that DMT's therapeutic effects can be neatly separated from the subjective experience.

The researchers themselves noted that DMT was administered alongside preparation sessions, a supportive therapeutic environment, and integration follow-up — and they could not determine whether the drug alone would have achieved the same results. This echoes a broader finding across psychedelic research: context matters. The drug opens a door, but what happens in the room appears to shape the outcome.

The clinical trials described above use isolated, pharmaceutical-grade DMT administered intravenously. But there is a parallel line of research examining ayahuasca itself — the traditional brew that contains DMT alongside harmala alkaloids contributed mostly by the Banisteriopsis caapi vine. This research is smaller in scale and less controlled, but it offers insights that isolated-DMT studies cannot, because it examines the compound as it has actually been used for centuries.

Small imaging studies have linked long-term ayahuasca use to increased cortical thickness in brain regions involved in attention and self-awareness [10]. Laboratory experiments have shown that ayahuasca's components — including the harmala alkaloids, not just DMT — stimulate the growth of new neurons in cell cultures [11]. A 2025 fMRI study found that machine learning could distinguish long-term ayahuasca users from non-users with 75% accuracy, based on brain activity patterns particularly in regions involved in emotion processing [12]. While these are observational findings that cannot prove causation, they suggest lasting changes in brain structure and function among regular users.

Brain imaging studies consistently show that ayahuasca modulates the default mode network (DMN) — reducing its activity during the acute experience and altering its connectivity patterns afterwards [13]. The DMN is associated with our sense of self, autobiographical memory, and habitual patterns of thinking. When it quiets down, those patterns loosen, and new possibilities emerge.

This is potentially significant for understanding depression and trauma, both of which involve being stuck in rigid, repetitive patterns of thought — rumination, self-criticism, re-experiencing traumatic memories. The temporary loosening of these patterns may be precisely what creates the opening for therapeutic change. EEG studies consistently show reduced alpha wave power and increased signal complexity during the ayahuasca experience [14], suggesting a brain state that is less constrained by its usual defaults.

Preclinical research has revealed that ayahuasca weakens the reconsolidation of traumatic fear memories in rats, with effects lasting over three weeks; specific serotonin receptors in the prefrontal cortex have been identified as critical mediators of this fear extinction [15]. A randomised, double-blind trial at the University of São Paulo is now comparing ayahuasca to esketamine for PTSD treatment [16] — one of the first controlled studies of ayahuasca specifically for trauma. Previous controlled data from Brazil lends support: a 2019 randomised, placebo-controlled trial at the Federal University of Rio Grande do Norte found that a single dose of ayahuasca produced rapid antidepressant effects in 29 patients with treatment-resistant depression, with a large effect size (d = 1.49 at day 7) [26].

Observational data from military veterans participating in ayahuasca retreats has shown meaningful symptom reductions — approximately 26% improvement on standardised PTSD measures [17]. These are not controlled trials, and they cannot rule out placebo effects or self-selection bias. But they provide encouraging signals that warrant more rigorous investigation.

A crucial finding from recent research concerns what happens after the ayahuasca experience. A 2025 analysis of over 10,000 ceremony attendees found that those with supportive settings and guidance reported significantly better long-term mental health outcomes, while those who felt isolated or unsafe had poorer outcomes [18]. Intriguingly, even challenging experiences — intense visions, difficult emotions — correlated with positive mental health later, provided they were processed in a supportive context.

This underscores a point that the clinical DMT trials also suggest: the quality of support around the experience matters. Whether we call it "psychotherapeutic support" (as the Erritzoe trial does) or "integration" (as the ayahuasca community does), the principle is the same. The compound may open a window of enhanced neural flexibility, but what happens during that window shapes the outcome.

It is important to be clear about what these different lines of research can and cannot tell us. The stroke and depression trials use isolated DMT, administered intravenously, in controlled medical settings. They tell us about DMT specifically. The ayahuasca studies examine the full brew — with all its pharmacological complexity — in ceremonial or therapeutic contexts. They tell us about ayahuasca.

The overlap is real, but more limited than often assumed. In brews that combine Banisteriopsis caapi with DMT-containing admixture plants, DMT is the principal visionary compound. But in several Indigenous traditions, ayahuasca refers to the vine alone — caapi without any DMT-containing plant — and these vine-only preparations, which are legal in most jurisdictions, are considered medicines in their own right. The contexts, dosing, route of administration, and pharmacology between clinical DMT and any form of ayahuasca are distinct. Ayahuasca contains MAO inhibitors that alter DMT's metabolism, extend its duration, and contribute their own therapeutic effects. Clinical IV DMT delivers a precise dose over minutes.

There are also dimensions of the ayahuasca experience that no clinical DMT trial captures — in particular, the role of the group setting. In traditional and contemporary ceremonial use, ayahuasca is almost always taken in community, with shared intention, music, and guidance. The contribution of this communal container to therapeutic outcomes has barely been studied, but is widely reported by participants and practitioners.

One of the most important findings from recent neuroplasticity research is that the enhanced brain flexibility induced by psychedelics does not end when the experience does. Evidence suggests that this window of heightened plasticity remains open for days or even weeks afterwards — a period when the brain is unusually receptive to forming new patterns and consolidating new insights.

A 2025 study published in Cell demonstrated that psilocybin-induced plasticity is activity-dependent: the neural changes that persist depend on what the individual is actually doing and thinking during the heightened plasticity window [19]. While this study used psilocybin rather than DMT, the underlying mechanism — TrkB-mediated synaptic growth — is shared across psychedelic compounds.

This has practical implications for anyone considering these treatments, whether in a clinical setting or a ceremonial context. The period following the experience — what clinicians call "the integration phase" — is when new neural patterns are being consolidated. Active engagement with the insights gained (through therapy, journalling, meditation, or behavioural change) may help cement beneficial patterns. Conversely, returning immediately to old environments and habits may cause the brain to simply reinforce its existing wiring.

The safety profile of both DMT and ayahuasca has been substantially clarified by recent research. A meta-analysis in JAMA Psychiatry found that serious adverse events occurred in 0% of healthy participants across psychedelic studies, and approximately 4% of those with pre-existing neuropsychiatric disorders [21]. Psychosis incidence ranged from 0.002% in population studies to 0.6% in clinical trials — low, but not zero [22].

For ayahuasca specifically, physical effects are common but usually benign: nausea and vomiting occur in approximately 68% of users, headache in 18%, but only 2.3% required any medical attention [23]. The Phase 1 IV DMT study provides additional reassurance: cardiovascular effects were mild (10–20 mmHg blood pressure elevation) and transient, with no ECG abnormalities.

All documented ayahuasca-related fatalities have involved polydrug use or unsupervised settings. This underscores the importance of proper screening and experienced facilitation.